Abstract
Seven patients with macroglobulinemia (six previously untreated, one with minimal pretreatment) were treated with fludarabine (25 mg/m2/day for 5 days, repeated every 4 weeks). The median age was 58 years. The time from diagnosis to treatment with fludarabine was 4.5 months to 175 months (median 32.6 months). The patients received six (n=5), five (n=1), and three (n=1) courses of fludarabine. One patient showed only a slight decrease of immunoglobulin (Ig) M (from 5750 mg/dl to 4700 mg/dl) and no improvement of anemia. Therefore, treatment was stopped after three cycles. In the other six patients, a marked reduction of IgM levels (from 6140 mg/dl to 1220 mg/dl median), a normalization of hemoglobin (from 10.8 g/dl to 12.3 g/dl median), a reduction of lymphocyte count (from 1992/μl to 652/μl median), and a reduction of β2 microglobulin (from 2.3 mg/l to 1.8 mg/l median) were achieved. A 50% IgM reduction was achieved 5.4 months (median) after the beginning of therapy, and the maximum response was observed 17.3 months (median) after the end of treatment. The responses were sustained without further therapy in six patients for 20.8–55.2 months. In one patient, disease progression was observed 12.5 months after the end of therapy. Fludarabine therapy was well tolerated with few side effects. In three patients, febrile episodes occurred. No opportunistic infections were recorded. We conclude that fludarabine is an effective treatment in previously untreated or in minimally pretreated patients with Waldenström's macroglobulinemia.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 11 October 1999 / Accepted: 16 February 2000
Rights and permissions
About this article
Cite this article
Thalhammer-Scherrer, R., Geissler, K., Schwarzinger, I. et al. Fludarabine therapy in Waldenström's macroglobulinemia. Ann Hematol 79, 556–559 (2000). https://doi.org/10.1007/s002770000185
Issue Date:
DOI: https://doi.org/10.1007/s002770000185